AdamSamuel Abdur-RahimSperlingMDPhD

Hematology • Boston, MA

Hematologic Oncology

Instructor in Medicine

Join to view full profile

Dr. Sperling is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sperling's full profile

Already have an account?

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-4218

Fax+1 617-632-4773

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2017 - 2018
Brigham and Women's HospitalResidency, Internal Medicine, 2011 - 2014
David Geffen School of Medicine at UCLAClass of 2011

Certifications & Licensure

MA State Medical License 2013 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Internal Medicine

Publications & Presentations

PubMed

Long-term persistent exposure to cigarette smoke induces AhR driven corneal endothelial dysfunction in mice.
Mohit Parekh, Yadav Adhikari, Neha Deshpande, Peter Miller, Adam S Sperling
Experimental Eye Research. 2024-11-01
1 citations
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma.
Jan H Frenking, Xiang Zhou, Vivien Wagner, Thomas Hielscher, Joseph Kauer
Journal for Immunotherapy of Cancer. 2024-10-07
1 citations
Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide.
Yuxin Liu, Clifton C Mo, Monique A Hartley-Brown, Adam S Sperling, Shonali Midha
Expert Review of Hematology. 2024-08-01

Abstracts/Posters

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Adam S Sperling, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

Watch: When Disease Impairs Immunity, Vaccines Are Hampered, TooOctober 29th, 2021